Mechanisms outpacing medicine in autoinflammatory diseases

By
Ruyue Chen
June 17, 2026
0 min

Frontiers In Immunology

Overview

This review highlights the gap between genetic understanding and therapeutic predictability in autoinflammatory diseases, emphasizing the need for a phenotype-weighted, organ-prioritized, and time-sensitive approach to treatment.

Background

Autoinflammatory diseases are characterized by unprovoked inflammation due to genetic defects, such as MEFV mutations in Familial Mediterranean fever. Understanding these diseases at the molecular level has advanced significantly, yet therapeutic options have not kept pace, leading to challenges in effective management.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

['Monogenic autoinflammatory diseases often do not follow a linear gene-to-pathway-to-therapy model.', 'Distinct genetic lesions can lead to similar clinical phenotypes, complicating treatment decisions.', 'Divergent organ involvement and therapeutic responses can arise from the same genetic defect.', 'Current treatment strategies should be informed by genotype, considering the dominant inflammatory module and organ-specific disease burden.', 'Phenotypic overlap may indicate shared downstream inflammatory pathways.', 'As diseases evolve, the mechanisms driving inflammation may change, necessitating a flexible treatment approach.']

Clinical Implications

Clinicians should adopt a nuanced approach to treating autoinflammatory diseases, integrating genetic insights with clinical phenotypes and organ-specific considerations to enhance treatment efficacy and patient outcomes.

Conclusion

The review advocates for a shift in treatment paradigms for autoinflammatory diseases, emphasizing the need for a comprehensive understanding of both genetic and phenotypic factors in therapeutic decision-making.